Mathew Bennett

Pervasis Therapeutics, Inc. is a clinical stage company developing a broad portfolio of biologically active therapeutics. The company was founded by Robert S. Langer Jr. and Helen Marie Nugent in 2004 and is headquartered in Waltham, MA.

Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers.

CereHealth Corp. engages in the production of brain imaging software by utilizing high resolution gamma cameras. It specializes in Single-Photon Emission Computed Tomography (SPECT) & Positron Emission Tomography (PET). The company is headquartered in Littleton, CO.

Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC.

Covington & Burling LLP provides legal services. It also provides support services in the following administrative departments including accounting, human resources, information research services, information technology services, library, operations, marketing, practice systems support, recruitment, attorney and alumni relations, and professional development. The company was founded by J. Harry Covington and Edward B. Burling on January 1, 1919 and is headquartered in Washington, DC.

Part of Roche Holding AG, Roche Diagnostics GmbH is a German company that develops innovative medicines, treatments, and diagnostics. The company is based in Mannheim, Germany. The CEOs of the company are Claudia Fleischer, Claus Haberda, Clemens Schmid. Roche Diagnostics was acquired by Roche Holding AG on January 01, 1999.

Xantos AG is a functional biology and drug discovery company developing biopharmaceuticals in the areas of cancer and metabolic diseases. Its business model is to develop drug discovery pipelines based on the validated targets and leads generated by its proprietary through target identification and validation system and to form indication specific joint research and development collaborations with pharmaceutical and biotechnology companies. It also offers customers its proprietary technology and cDNA/siRNA screening tools for research service deals. The company is headquartered in Munich, Germany.

Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark.

The North Carolina Biotechnology Center provides research and education grants. Its services include financing, technology assessment, business planning, and marketing strategies implementation. The company was founded in 1984 and is headquartered in Research Triangle Park, NC.

Critical Path Institute is a nonprofit organization established in 2005 as a public and private partnership with the FDA's Critical Path Initiative program. The non-profit company is based in Tucson, AZ, and operates from Ireland with additional staff in multiple other locations. The company's mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. The company orchestrates the development of drug development tools through an innovative, collaborative approach to the sharing of data and expertise, and accelerate the pace and reduce the costs of medical product development by building consensus among the participating institutions. The company was founded in 2005 by Raymond L. Woosley, Glenn C. Rice. Daniel M. Jorgensen has been the CEO of the company since 2022.

JenaValve Technology GmbH develops and manufactures transcatheter valve implantation systems for transapical and transfemoral implantation. The firm offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The company was founded by Markus Ferrari, Volker Guyenot and Hans-Reiner Figulla in 2006 and is headquartered in Munich, Germany.

Kearny Venture Partners (Kearny Venture Partners) is a venture capital firm. The firm is headquartered in San Francisco, California.

Contera Pharma ApS is a holding company that identifies and develops treatments for patients suffering from movement disorders. It develops drug candidates based on a combination of repositioning, combinations, and reformulations. The firm's lead project JM-010 is for treatment of dyskinesia associated with Parkinson's disease. It develops an approach of using a combination therapy to tackle clinically relevant synergistic pathways to obtain therapeutic effects which will generate efficacious therapeutic entities based on robust pre-clinical and clinical evidence. The company was founded by Mikael Søndergaard Thomsen and John Bondo Hansen in 2010 and is headquartered in Copenhagen, Denmark.

Tube Pharmaceuticals GmbH develops a new class of anti cancer drugs. Its products include Tubulysins and their synthetic analogs and next generation Epothilones. The company assets are natural product classes and their synthetic analogues comprising a product platform with multiple partnering and development opportunities. It focuses on synthetic substances for the cancer therapy, derived from natural substances. The company was founded in 2011 and is headquartered in Vienna, Austria.

Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland.

Life Line Screening Holdings LLC is a private company that provides annual screenings for risks of cardiovascular disease, stroke, and other chronic diseases. The company is based in Austin, TX. The company's screenings are designed by doctors and administered by trained professionals to help detect hidden health issues before they become a serious problem. The company offers a high sensitivity c-reactive protein test (hs-crp test) to detect inflammation in the body, which can indicate the presence of atherosclerosis. The company also provides type 2 diabetes test and diagnosis services. The company was founded in 1993 and the CEO is Matt Miller.

Apeiron Partners LLC provides investment advice. The private company is based in Boston, MA. The company was founded by Jeffrey D. Wager.

Pendulum Therapeutics, Inc. engages in the development of therapeutics and diagnostics that target the human microbiome to improve the lives of patients suffering from various diseases. Its product pipeline includes WBF-011, WBF-020, WBF-012, and WBF-014.. The company was founded by Colleen Cutcliffe, John Eid, and James Bullard in 2012 and is headquartered in San Francisco, CA.

Epiva Biosciences, Inc. develops immunobiotic therapeutics. The company is headquartered in Cambridge, MA.

EnBiotix, Inc. operates as a late clinical-stage respiratory therapeutics company, which engages in deploying novel systems and synthetic biology technologies. It offers anti-persisters, engineered bacteriophage, tunable target degradation, and systems biology platform. Its pipeline includes ColiFin, EBX-001, EBX-002, and Linear Peptide Antibiotics. The company was founded by James J. Collins in 2012 and is headquartered in Boston, MA.

Censhare AG develops online platform which pools all marketing and communications content within one information-centric system. The company is headquartered in Munich, Germany.

Placon Therapeutics, Inc. develops novel platinum therapies. The private company is based in Watertown.

California Life Sciences Association (CLSA) is the largest and most influential life sciences advocacy and business leadership organization in California. The non-profit company is based in South San Francisco, CA, and has offices in other locations as well. The company works closely with industry, government, academia, and others to shape public policy, improve access to innovative technologies, and grow California's life sciences economy. CLSA serves biotechnology, pharmaceutical, medical device, and diagnostics companies, research universities and institutes, investors, and service providers throughout the state. Mike Guerra has been the CEO of the company since 2019.

Advertima AG is a Swiss computer vision company that digitizes customers in stores and transforms grocery stores into a profitable retail media network. The company is based in St. Gallen, Switzerland. The company provides insights from their success stories and offer information on retail media and performance media data through their news and blog articles. Advertima was founded in 2016 by Mario Siano, Simon Ebner, Iman Nahvi, and Amir Nahvi, with Iman Nahvi serving as the CEO since 2016.

Colabs International Corp. is a pharmaceutical company that develops formulations and medicines. The company’s targeted epidermal-drug delivery system which is identified as QuantaSphere Technology for cosmeceuticals, fragrances, antibacterial, anti-viral sanitizers, cleaners, and topical pharmacology. It also offers sunscreen, pest repellents, and sanitizers, soap distribution for the firm’s Klenskin products internationally. Its QuantaSphere Technology formulations provide proprietary, epidermal therapeutic effects and also blends consumer needs for a healthy lifestyle with targeted, eco-friendly, multi-tasking products. The company was founded by Laura Cohen and Lisa Leblanc on August 5, 2008 and is headquartered in Huntington Beach, CA.

ImmuneID, Inc. is a precision immunology company that combines next-generation sequencing with protein display technologies to develop novel therapies for immune diseases. The company's proprietary platform identifies millions of antibody-target interactions to build the map of human immunity, which helps to improve and personalize patient diagnoses for precise treatments. The company was founded in 2020 by Longwood Fund and is headquartered in Boston, MA. James S. Scibetta has been the CEO of the company since 2021.

Atelerix Life Sciences, Inc. is a pharmaceutical company that is developing a new drug, ATLX-0199, to address the unmet need of opioid-induced respiratory depression (OIRD) in surgical patients. The company is based in Charlottesville, VA. Atelerix Life Sciences was founded by David G. Kalergis, Benjamin Gaston, James Bates, and Stephen Lewis, with David G. Kalergis serving as the CEO since incorporation. The current drug for OIRD, Naloxone, is problematic and used infrequently because it reverses pain relief. ATLX-0199 safely stimulates opioid-depressed respiratory drive without interfering with opioid-induced analgesia.

Solu Therapeutics is an American precision-medicine company focused on developing therapeutics to eliminate disease-driving cells in cancer, immunology, and autoimmunity. The company is located in the US. The company's proprietary cytotoxicity targeting chimera (cytac) platform and drug candidates, licensed from GSK, unlock antibody-intractable cell surface targets, providing the capability to develop next-generation medicines that harness the power of biologics with the vast target binding space of small molecules.